after terminating 3 of the 7 trials they had going including 2 phase II trials. Now if they get good results in Jan 2010 and get up front payments, maybe CYCC wants to restart the t-cell lymphoma and the lung cancer trial.

Company is banking it all on the trial concluding now.

However, at $24 Million market cap, they could get an upfront payment equal to 1.5 X the total value of the whole company.

crapshoot.

robj